logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2020 – Add-on tucatinib improves survival in HER2+ breast cancer with brain metastasis

This response rate is more than double that in the phase 2 HER2CLIMB study.